Year Established 2015
Type of Organisation
Website Address www.iqseries8.com

Physical Address Level 7, 222 Clarence Street,


Sydney, New South Wales 2000
Telephone:
+61 8239 5400
Fax
+61 8362 9547
Key Contact
Name
Ms Jacqueline Rachelle Yee
Position
Head, Investment Strategy
Email
[email protected]
Mobile
+61 437 717 655
The iQ Series 8 Life Science Fund (Global) ESVCLP
LP presents a unique opportunity for both
innovative early-stage companies to access
venture capital and sophisticated investors to
participate in structured investments in the
medical life science and biotechnology sector.
The Fund invests in early-stage private life science
companies primarily focused on biotechnology
innovations with the potential to improve health
and disease outcomes. The Fund seeks private
companies that are actively involved in the late
discovery stage or the preclinical development
stage of new medicines and medical technologies
– for example, biologic compounds, chemical
compounds, diagnostics and medical devices.
The Fund is a closed-end, 6-7 year term,
AUD100million specialist fund that provides
investors entry to investment opportunities in the
life science sector not normally accessible for
direct investment.
Early Stage Venture Capital Limited Partnership
(ESVCLP) LP
Incorporated Limited Partnership (NSW)
Registered Closed-End Wholesale Fund
Services Offered






Investing in late-discovery and preclinical stages
Investing in chemical compounds, biotechnology
(biologics), diagnostics, medical devices.
Medical life science and biotechnology expertise
Experienced investment managers
Strategic and structured investments
Actively managed investment portfolio
Under the ESVCLP program, investors in the Fund are
exempt from Australian income tax on distributions
of income derived from Eligible Venture Capital
Investments held by the Fund, thereby making the
Fund an attractive vehicle for prospective investors
to access such investments.
The iQ Series 8 Funds will expand, in 2016, to include
a complementary new investment fund, extending
the horizon to distinctive life science investments,
with deeper access to capital for investee companies
and further diversified investment opportunities to
investors. The full iQ Series 8 Funds suite, a
AUD300million aggregate investment fund series, is
predominantly dedicated to Australian early stage
medical life science and biotechnology companies.
Contact us today:
+61 8239 5400
[email protected]
www.iqseries8.com
A member of The iQ Group Global Companies